Trianni
Trianni is a privately held San Francisco biotech platform company, founded in 2010, that provides a proprietary platform for isolating fully-human monoclonal antibodies for pharmaceutical and biotech customers.
- Company typePublic
- Founded2012
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Trianni does
Trianni is a small, privately held biotechnology company founded in 2010 and based in San Francisco, California. Per the firmographic description, the company operates a platform dedicated to the isolation of fully-human monoclonal antibodies, implying use of a transgenic-mouse-based discovery approach that generates human-sequence antibody candidates for downstream therapeutic or diagnostic use. The company's stated operational footprint is 1-10 employees, indicating a lean, technology-focused organization rather than a scaled commercial enterprise. The website is trianni.com and the company is registered as a for-profit private entity with no IPO.
The input does not provide direct evidence about Trianni's specific technology architecture, named products, customer relationships, or revenue mechanics. The only operational data points available are a general contact phone number (604.559.9005) and the absence of disclosed management team profiles, regulatory actions, mergers and acquisitions, or corporate structural moves. No funding rounds, strategic partnerships, or product launches are documented for Trianni in the supplied material. As a result, a complete assessment of Trianni's business model, GTM motion, and competitive positioning cannot be constructed from this dataset alone; the analysis must rely on the limited firmographic data supplemented by the company's stated platform description.
Trianni firmographics
Firmographics- Name
- Trianni
- Legal name
- AbCellera Biologics Inc.
- Website
- https://trianni.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Trianni is a privately held San Francisco biotech platform company, founded in 2010, that provides a proprietary platform for isolating fully-human monoclonal antibodies for pharmaceutical and biotech customers.
- Ownership category
- akta.pro rank
Trianni industry classification
Industry- Product category
- Antibody Discovery Platform
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where Trianni is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Trianni business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Fee-for-service Discovery Programs: Previously operated as a fee-for-service model providing antibody discovery services to pharmaceutical partners. Partnered with 40+ companies on 100+ antibody drug programs since 2015.
- Internal Pipeline Development: Transitioning to capture full product revenues through proprietary antibody programs. Currently advancing three internal antibodies (ABCL635, ABCL575, ABCL688) through clinical development.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Trianni product offering
Product offeringCore offering
Trianni provides a proprietary platform for the isolation of fully-human monoclonal antibodies. The platform is built on transgenic mouse technology designed to enable direct generation of human antibody sequences for therapeutic discovery. It is offered to pharmaceutical and biotechnology partners as a tool to accelerate antibody-based drug development.
Product overview
AbCellera operates as a clinical-stage biotech company with a vertically integrated antibody discovery platform. The platform integrates microfluidics, AI, and transgenic mouse technologies to generate multiple drug candidates in parallel. The company is advancing its own internal pipeline of proprietary antibody programs including ABCL635 (endocrine/women's health, Phase 1/2), ABCL575 (immunology/inflammation, Phase 1), ABCL688 (autoimmunity, IND-enabling), and ABCL386 (oncology, discovery), while also maintaining 100+ partnered discovery programs with major pharmaceutical companies. The company has transitioned from a fee-for-service model toward capturing full product revenues from its proprietary pipeline.
Differentiator
Problem solved
Functional benefit
Products and services
- Trianni Mouse Platform A proprietary transgenic mouse-based platform that enables the isolation of fully-human monoclonal antibodies for use in therapeutic discovery. It is targeted at pharmaceutical and biotechnology companies that require direct access to human antibody repertoires without traditional humanization steps.
Quantifiable outcome
- 134% year-over-year revenue growth in Q2 2025
- +1 more outcomes
Companies that use Trianni
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles1 record
Trianni technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Trianni partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Major Pharma Companiescore100+ partnered discovery programs with major pharmaceutical companies. Operates 40+ partnerships for antibody drug development since 2015.
Scale indicators9 records
Trianni competitors and assessment
Company assessmentBroad incumbents
- Distributed Bio (Charles River Laboratories): Charles River's antibody discovery franchise (incorporating Distributed Bio's SuperHuman and other platforms) competes with Trianni across both transgenic-mouse and display-based antibody discovery offerings.
- Regeneron Pharmaceuticals (VelocImmune): Operates the proprietary VelocImmune transgenic mouse platform as part of a much larger fully integrated biopharma business; while VelocImmune is largely captive, the underlying technology is comparable to Trianni's approach.
Direct peers
- Harbour BioMed: Operates the Harbour Mice transgenic platform for fully human monoclonal antibody discovery, directly competing with Trianni's transgenic mouse technology for biopharma licensing and partnered discovery programs.
- Biocytogen: Operates RenMab, RenLite, and other transgenic mouse platforms for fully human antibody discovery, with a RenBio operating model offering antibodies and target validation services — directly comparable to Trianni's value proposition.
- Ligand Pharmaceuticals (OmniAb): OmniAb provides transgenic animal-based antibody discovery platforms (OmniRat, OmniMouse, OmniFlic, OmniClic), directly comparable to Trianni's fully human antibody platform for biopharma partners.
- Ablexis (AlivaMab): Develops the AlivaMab transgenic mouse platform for human antibody discovery; comparable to Trianni's platform and historically a direct competitor for biopharma licensing deals.
Others
- AbCellera: Parent organization that integrated Trianni's transgenic mouse technology into its vertically integrated microfluidics, AI, and transgenic mouse antibody discovery platform; relevant as both the integrating party and the most direct platform comparator for Trianni's offerings.
Emerging players
- Kymab (Sanofi): Operated the IntelliSelect transgenic mouse-based antibody discovery platform before acquisition by Sanofi; comparable to Trianni as a specialized transgenic-mouse antibody discovery asset, now part of a large pharma parent.
- Cyagen Biosciences: Provides custom transgenic mouse models and antibody discovery services; overlaps with Trianni on the transgenic-mouse production and licensing side, particularly in the Asia-Pacific market.
Regional players
- GenOway: European-based provider of transgenic mouse models and custom genetic engineering for research and antibody discovery, comparable to Trianni's underlying mouse engineering capability but with primarily European geographic reach.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks4 records
Key highlights4 records
Customer concentration
Trianni social profiles
Digital presenceTrianni financial estimates
Financial estimateRevenue estimate
Valuation estimate
Trianni leadership team
Management profileNumber of profiles
Trianni funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Trianni M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Trianni
What does Trianni do?
Trianni provides a proprietary platform for the isolation of fully-human monoclonal antibodies. The platform is built on transgenic mouse technology designed to enable direct generation of human antibody sequences for therapeutic discovery. It is offered to pharmaceutical and biotechnology partners as a tool to accelerate antibody-based drug development.
Is Trianni a public or private company?
Trianni is a public company. It is classified as corporate owned and is currently operating.
When was Trianni founded?
Trianni was founded in 2012. It employs 1 to 10 people.
Where is Trianni based?
Trianni is headquartered in San Francisco, United States, in the North America region.
How does Trianni make money?
Two revenue lines are on record. Fee-for-service Discovery Programs are the primary driver. The others are internal Pipeline Development.
Who are Trianni's main competitors?
Broad incumbents on record are Distributed Bio (Charles River Laboratories) and Regeneron Pharmaceuticals (VelocImmune). Direct peers are Harbour BioMed, Biocytogen, Ligand Pharmaceuticals (OmniAb) and Ablexis (AlivaMab). AbCellera is listed as an others. Emerging players are Kymab (Sanofi) and Cyagen Biosciences. GenOway is listed as a regional player.
Does Trianni have an API?
No public API is recorded for Trianni.
What industry is Trianni in?
Trianni's product category is Antibody Discovery Platform. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization).